H.C. Wainwright downgraded Hookipa Pharma (HOOK) to Neutral from Buy without a price target after the company entered into a non-binding agreement with Poolbeg for an all-stock acquisition of Poolbeg. The firm believes it would be prudent to await more clarity on the company’s path forward before projecting the cadence of potential revenue at this time.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
- Hookipa Pharma to acquire Poolbeg Pharma
- Hookipa Pharma downgraded to Sector Perform from Outperform at RBC Capital
- Hookipa Pharma price target lowered to $7 from $24 at JMP Securities
- Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program